# hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

> **NCT02960594** · PHASE1 · COMPLETED · sponsor: **Inovio Pharmaceuticals** · enrollment: 93 (actual)

## Conditions studied

- Breast Cancer
- Lung Cancer
- Pancreatic Cancer
- Head and Neck Cancer
- Ovarian Cancer
- ColoRectal Cancer
- Gastric Cancer
- Esophageal Cancer
- HepatoCellular Carcinoma

## Interventions

- **BIOLOGICAL:** INO-1400
- **BIOLOGICAL:** INO-9012
- **BIOLOGICAL:** INO-1401

## Key facts

- **NCT ID:** NCT02960594
- **Lead sponsor:** Inovio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2018-11-09
- **Final completion:** 2018-11-09
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2018-11-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02960594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02960594, "hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02960594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*